Flexion Therapeutics (NASDAQ:FLXN) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.01, Fidelity Earnings reports. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. The business had revenue of $21.79 million during the quarter, compared to analysts’ expectations of $18.85 million.
FLXN stock traded down $0.69 during mid-day trading on Friday, hitting $16.43. 1,132,400 shares of the company were exchanged, compared to its average volume of 622,178. The business has a 50 day simple moving average of $14.85 and a 200-day simple moving average of $12.36. The stock has a market capitalization of $655.05 million, a PE ratio of -3.66 and a beta of 1.38. Flexion Therapeutics has a 1-year low of $8.76 and a 1-year high of $17.82. The company has a current ratio of 7.80, a quick ratio of 7.33 and a debt-to-equity ratio of 3.95.
A number of equities analysts recently commented on the company. Northland Securities set a $20.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 10th. BidaskClub upgraded Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 5th. ValuEngine cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Finally, Zacks Investment Research cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.57.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: What is the Beige Book?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.